Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
Classes of Biologics for the Treatment of IBD - ALPCO
Mechanism of Action | Entyvio® (vedolizumab)
Upadacitinib for Crohn's Disease and Ulcerative Colitis Treatment: Hitting the Selective JAKpot - Gastroenterology
Tofacitinib in ulcerative colitis | Immunotherapy
Mechanism of vedolizumab. This image is modified from their original... | Download Scientific Diagram
Ulcerative Colitis - Gastrointestinal Disorders - Merck Manuals Professional Edition
STELARA® (ustekinumab) Mechanism of Action: Plaque Psoriasis
Frontiers | Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? | Medicine
Antibody treatment of ulcerative colitis - ScienceDirect
Interrogating host immunity to predict treatment response in inflammatory bowel disease | Nature Reviews Gastroenterology & Hepatology
New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound - Gastroenterology
Classes of Biologics for the Treatment of IBD - ALPCO
Ulcerative colitis - The Lancet
Vedolizumab | New Drug Approvals
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program | SpringerLink
The alleviating effect and mechanism of Bilobalide on ulcerative colitis - Food & Function (RSC Publishing)
Mechanism of Action | Entyvio® (vedolizumab)
Nutrients | Free Full-Text | Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions | HTML
Vedolizumab for the treatment of ulcerative colitis and Crohn's disease | Immunotherapy